Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models

Tadafumi Tamura*

Marketing Department Sales & Marketing Division and Pharmacological Research Laboratories, Research Division, Kyowa Hakko Kirin Co., Ltd., Tokyo 100-8185, Japan

Background: Olopatadine hydrochloride ophthalmic solutions are treated for allergic conjunctival diseases that are a selective histamine H1 receptor antagonist and an inhibitor of the release of mediators including histamine from the human mast cells. Substance P (SP) levels are increased in tears of patients with allergic conjunctivitis. However, little is known about the regulation of SP release by anti-allergic ophthalmic solutions.

Objective: We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions.

Methods: Conjunctivitis was induced by subconjunctival injection of histamine or intravenous injection of ovalbumin in rats passively sensitized with anti-ovalbumin anti-serum. The releases of SP were determined in the conjunctiva and tears using rat antigen-induced conjunctivitis models.

Results: Olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked in the histamine- or antigen-induced hyperpermeability. The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions. Moreover, olopatadine significantly inhibited the release of SP from the conjunctiva.

Conclusion: These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.

Key words: Olopatadine hydrochloride; Ophthalmic solution; Substance P; Allergic conjunctivitis; Rat

INTRODUCTION

Allergic diseases such as seasonal or perennial allergic conjunctivitis (AC) are closely related to a type I allergic reaction triggered by the allergen on the conjunctival mast cell. AC is caused by an allergen-induced inflammatory response, in which allergen-specific IgE antibodies bind to mast cells in the conjunctiva, triggering the release of chemical mediators,
including histamine and cytokines. Histamine binding to its receptors plays a central role in the induction of major allergic symptoms such as itching.

Choices for the treatment of AC are anti-allergy ophthalmic solution, steroid ophthalmic solution, and immunosuppressant ophthalmic solution; the first choice for the subject to the immediate phase of allergic inflammation may be anti-allergic ophthalmic solution.

Olopatadine hydrochloride ophthalmic solution (olopatadine) inhibits the binding of histamine to histamine H1 receptor, with superior histamine H1 receptor selectivity [1-3]. Olopatadine has also been shown to stabilize human conjunctival mast cells [1, 3, 4]. It has been reported that substance P (SP) levels are increased in tears of patients with AC compared with healthy individuals, suggesting that SP may contribute to the pathogenesis and severity of AC [5-7]. There are a variety of known itch-associated mediators in dermatitis, including histamine, neuropeptides (SP, calcitonin gene-related peptide, etc.), opioids, growth factors, cytokines, etc [8, 9]. Oral olopatadine was reported to mitigate cutaneous inflammation and the increased number of scratching episodes in a mouse model of chronic inflammatory dermatitis, accompanied by decreased cytokine and SP productions [10, 11]. However, little is known about the regulation of SP release by anti-allergic ophthalmic drugs in AC.

The aim of this study is to supplement the known pharmacological profile of olopatadine with the commonly used anti-allergic ophthalmic solutions, levocabastine and tranilast in experimental rat conjunctivitis models. In addition, the release of SP was determined in the conjunctiva and tears using rat antigen-induced conjunctivitis models.

MATERIALS AND METHODS

Rats

Male 6-week-old Wistar rats were purchased from Charles River Japan (Japan). Animals were maintained at 19-25°C with 30-70% of humidity on a 12 h light/dark cycle (light on at 7:00), and had free access to commercial pellets and water. Experiments were performed in accordance with recommendations of the institutional animal care and use committee of the Kyowa Hakko Kirin Co., Ltd. (Japan).

Reagents

Ophthalmic solutions used in this study were olopatadine hydrochloride ophthalmic solutions (Patanol® ophthalmic solution 0.1%, olopatadine 0.1%; Kyowa Hakko Kirin, Japan and Pataday™ ophthalmic solution 0.2%, olopatadine 0.2%; Alcon Laboratories, USA), levocabastine ophthalmic solution (Livostin® Eye Drops 0.025%, levocabastine; Janssen Pharmaceutical, Japan), and tranilast ophthalmic solution (Rizaben® Eye Drops 0.5%, tranilast; Kissei Pharmaceutical, Japan). Reagents used in this study were histamine dihydrochloride (Histamine; Sigma-Aldrich, USA), albumin (Ovalbumin, OVA; Sigma-Aldrich, USA) and Evans blue (Sigma-Aldrich, USA).

Histamine-induced conjunctival vascular hyperpermeability in rats

To compare the anti-histamine efficacy, conjunctival vascular hyperpermeability was induced by histamine in rats. Rats were injected with 30 μL of histamine (0.1 mg/mL) by the upper subconjunctiva under isoflurane anesthesia immediately after the intravenous injection of 1.5 w/v% Evans blue solution. Thirty min later, the animals were sacrificed and the bluing eye (eyelids and eyeballs) was removed. Dye which had leaked into the tissue was extracted with formamide at 45°C and its absorbance at 625 nm was determined with a spectrophotometer (THERMOmax™; Molecular Devices, USA). Values were analyzed as per weight of each organization. Ophthalmic solutions or saline were applied to the eyes (10 μL per eye) 30 min prior to the challenge of histamine. As negative control, rats were injected with 30 μL of saline by the upper subconjunctiva and were injected with 1.5 w/v% Evans blue solution.

Antigen-induced conjunctival vascular hyperpermeability in passively sensitized rats

 Conjunctival vascular hyperpermeability were induced by an experimental AC in passively sensitized rats. Anti-OVA antiserum containing IgE antibody was prepared by the method of Stotland and Share [12] using male rats. Rats were passively sensitized with 30 μL of anti-OVA antiserum by the upper subconjunctival injection under isoflurane anesthesia. Forty-eight h after the sensitization, the animals were subjected to challenge by an intravenous injection of OVA (2 mg/mL) solution containing 1.5 w/v% Evans blue. Thirty min later, the animals were sacrificed and the bluing eye (eyelids and eyeballs) was removed. Dye which had leaked into the tissue was determined by the method described
Olopatadine drop suppresses substance P release above. Ophthalmic solutions or saline were applied to the eyes (10 μL per eye) 30 min prior to the challenge of antigen. As negative control, sensitized rats were injected with 1.5 w/v% Evans blue.

**The onset and duration of action of olopatadine on the conjunctival vascular hyperpermeability in antigen-induced conjunctival vascular hyperpermeability**

Conjunctival vascular hyperpermeability were induced by an experimental AC in passively sensitized rats. Ophthalmic solutions or saline were applied to the eyes (10 μL per eye) 24 h, 6 h prior to the challenge of antigen, or 5 min after the challenge of antigen. As negative control, sensitized rats were injected with 1.5 w/v% Evans blue.

**Measurement of SP in conjunctiva**

We determined the levels of SP in the conjunctiva using rat antigen-induced conjunctivitis models. Sensitized rats were subjected to challenge by an intravenous injection of OVA solution. Ophthalmic solutions were instilled at 30 min before antigen challenge and immediately after antigen challenge into the bilateral eye with 10 μL/site. Thirty min later, the animals were sacrificed and the conjunctivas were removed. The removed tissue was homogenized in phosphate buffered saline containing the protease inhibitor. After centrifugation, the supernatant was collected and stored at −35°C. SP levels were determined using commercial SP assay kit (Cayman Chemical, USA) according to the provided protocol. The absorbance was measured using a microplate spectrophotometer. The determined values were analyzed as values per total protein. The percentage of SP release calculated [13]: SP release (%) = [(Average of SP level of the conjunctiva in the pre group) − (Average of SP level of the conjunctiva in the control group or the drug treated group)] / (Average of SP level of the conjunctiva in the pre group) × 100.

**Measurement of SP in tears**

Moreover, we determined the levels of SP in tears using rat antigen-induced conjunctivitis models. Another sensitized rat was subjected to challenge by an intravenous injection of OVA solution. Thirty min later, 50 μL saline was applied to both eyes. This procedure was repeated 3 times and a 200 μL sample was carefully collected from both eyes. After centrifugation, the supernatant was collected and SP levels were determined using commercial SP assay kit according to the provided protocol. The determined values were analyzed as values per total protein.

**Statistical analysis**

Data were presented as means ± SE. The Aspin-Welch test or Student’s t-test following the F-test was used for analysis of differences between two groups. Values of \( p < 0.05 \) were considered statistically significant.

**RESULTS**

**Histamine-induced conjunctival vascular hyperpermeability in rats**

The amount of dye leaked by the injection of histamine into the upper subconjunctiva was significantly increased compared to saline-injected animals (\( p < 0.0001 \)) (Fig. 1A). Olopatadine 0.1% and olopatadine 0.2% significantly suppressed the increased conjunctival dye leaked (\( p < 0.0001, \ p < 0.0001 \)). Levocabastine also significantly inhibited the increased conjunctival dye leaked by histamine (\( p = 0.0007 \)). Tranilast did not significantly inhibit. These inhibitory effects of olopatadine were more potent than for other tested anti-allergic ophthalmic solutions.

**Antigen-induced conjunctival vascular hyperpermeability in passively sensitized rats**

To elucidate the ocular anti-allergic efficacy of olopatadine and other anti-allergic ophthalmic solutions, we investigated in rat antigen-induced conjunctivitis models (Fig. 1B). The amount of dye leaked by the intravenous injection of OVA was significantly increased compared to saline-injected animals (\( p < 0.0001 \)). When olopatadine 0.1% and 0.2% were instilled into rats eyes 30 min before antigen challenge, the increased conjunctival dye leaked were significantly suppressed at both concentrations (\( p < 0.0001, \ p < 0.0001 \)). Levocabastine and tranilast also significantly inhibited the increased conjunctival dye leaked by antigen (\( p = 0.0001, \ p = 0.0061 \)). These inhibitory effects of olopatadine were more potent than for other tested anti-allergic ophthalmic solutions.

**The onset and duration of action of olopatadine on antigen-induced conjunctival vascular hyperpermeability in passively sensitized rats**

Next, the onset and duration of action of olopatadine on the conjunctival vascular hyperpermeability were investigated in rat AC (Fig. 2). Ophthalmic solutions were applied topically onto eyes 24 h or 6 h prior to the challenge of antigen, or 5 min after the challenge of antigen. Pre-treatment 6 h with olopatadine 0.1%
and 0.2% significantly inhibited the increased conjunctival dye leaked by 75.7% and 89.2% inhibition ($p < 0.0001$, $p < 0.0001$). Pre-treatment 24 h with olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked by antigen by 71.6% and 80.4% inhibition ($p = 0.0001$, $p = 0.0003$). Moreover, when ophthalmic solutions were applied to the eyes 5 min after the challenge of antigen, olopatadine 0.1% and 0.2% also significantly inhibited the increased conjunctival dye leaked by 59.7% and 77.8% ($p = 0.0006$, $p = 0.0002$).

Effect of olopatadine on SP release from the conjunctiva

Fig. 3A shows the effect of olopatadine and other anti-allergic ophthalmic solutions on SP release from the rat conjunctiva. SP contents in the conjunctiva was increased significantly by the OVA sensitization compared with normal rats ($p = 0.0088$), while it was decreased significantly after the OVA challenge ($p = 0.0044$), and the percentage of SP release by the OVA challenge was 33.1% (Fig. 3B). Olopatadine 0.1% and 0.2% significantly inhibited the decreased conjunctival SP contents ($p = 0.0324$, $p = 0.0040$), and their percentages of SP release were 13.7% and 8.2%. Therefore, olopatadine inhibited SP release from the conjunctiva. On the other hand, other anti-allergic ophthalmic solutions did not inhibit the decrease in the levels of SP.

Effect of olopatadine on the levels of SP in tears

To elucidate the SP release of olopatadine and other anti-allergic ophthalmic solutions, we determined the levels of SP in tears using rat antigen-induced conjunctivitis model (Fig. 4). The levels of SP in tears were significantly increased by the OVA challenge compared with normal rats. Olopatadine 0.1% and 0.2% significantly inhibited the increase in the levels of SP in tears ($p = 0.0054$, $p = 0.0005$). The levels of SP in tears after application of olopatadine 0.2% was significantly less than those of application of olopatadine 0.1% ($p = 0.0225$). Tranilast also significantly inhibited the increase in the levels of SP ($p = 0.0392$). On the other hand, levocabastine did not inhibit the increase in the levels of SP.
DISCUSSION

In this study, a rat model of conjunctivitis was used to examine the ocular anti-histamine and anti-allergic efficacies of olopatadine ophthalmic solution compared with other anti-allergic ophthalmic solutions. The present study also demonstrated that the SP levels were decreased in the conjunctiva and increased in tears in rat antigen-induced conjunctivitis models. This is in agreement with the clinical studies [5, 14], which showed that the level of SP in tears was abundant at the onset of allergy symptoms.

The different mechanisms of action of the anti-allergic ophthalmic solutions possibly account for the observed differences in efficacy. Olopatadine ophthalmic solution is a highly effective dual-action drug with selective histamine H1 receptor antagonistic action and human conjunctival mast cell stabilization action. Levocabastine is a histamine H1 receptor antagonist. Tranilast is characterized as a mediator release inhibitor. At first, to compare the anti-histamine efficacy, conjunctival vascular hyperpermeability was induced by subconjunctival injection of histamine. It has demonstrated that olopatadine ophthalmic solution inhibits binding of histamine to H1 receptors, with superior H1 receptor selectivity compared with other anti-allergic ophthalmic solutions [1-3]. In this study, olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked in the histamine-induced hyperpermeability model. These anti-histamine effects were more potent than for other tested anti-allergic ophthalmic solutions. In contrast, tranilast did not significantly inhibit.

Next, to compare the anti-allergic efficacy, antigen-induced conjunctivitis model was induced by intravenous injection of OVA in rats passively sensitized with anti-OVA antiserum. The inhibitory effects of olopatadine ophthalmic solutions in rat antigen-induced conjunctivitis models also were more potent than for other tested
anti-allergic ophthalmic solutions. In this model, tranilast also significantly inhibit it.

Histamine and various cytokines are released from conjunctival epithelial cells and mast cells by antigen-antibody reaction [1-3]. Olopatadine ophthalmic solution has been shown to suppress the histamine release in a concentration-dependent manner from human conjunctival mast cells [4, 15]. These effects of olopatadine 0.1% and 0.2% are continued and faster than other tested anti-allergic ophthalmic solutions on the conjunctival vascular permeability in antigen-induced conjunctivitis models.

So, the levels of histamine and SP in the conjunctiva and tears were actually determined in rat antigen-induced conjunctivitis models. Histamine levels were decreased by antigen-antibody reaction, but histamine levels in tears were not influenced (data not shown). SP levels in the conjunctiva were decreased and SP levels in tears were increased, suggesting that SP was released from the conjunctiva due to antigen-antibody reaction. Although SP induced the conjunctivitis in guinea pig, histamine level in the conjunctiva had no influence [4]. SP may be involved in the conjunctivitis not through histamine. In the dermatitis, SP is released from sensory nerve endings and cause histamine release from mast cells [16]. The visual analogue scale (VAS) score, which evaluated the subjective symptoms of ocular allergy, at the onset of symptoms correlated with tears histamine levels. It has been reported that olopatadine ameliorated the VAS score and decreased the SP levels in tears at the onset of ocular symptoms [14]. In the present study shows that SP are released in tears and may play a role in rat antigen-induced conjunctivitis models. Olopatadine ophthalmic solutions significantly inhibited the release of SP from the conjunctiva and the amount of SP in tears. On the other hand, tranilast significantly inhibited the amount of SP in tears, and levocabastine failed to inhibit the release of SP from the conjunctiva and the amount of SP in tears. The VAS score at the onset of symptoms correlated with histamine levels in tears [14]. Although SP also plays an important role in inflammation caused by an increase in vascular permeability, ocular allergy symptoms may be mainly induced by vasoactive amines in rat antigen-induced conjunctivitis models. Therefore, it is suggested that anti-allergic ophthalmic solutions suppressed the conjunctival vascular hyperpermeability in rat antigen-induced conjunctivitis models.

The effects of olopatadine 0.2% to the conjunctival vascular hyperpermeability were showing a strong tendency compared with those of olopatadine 0.1%, especially, the inhibitory of SP release to tears was significantly strong. SP is known itch-associated mediators in dermatitis, however, little is known about the association in AC. It has been reported that oral olopatadine attenuates the amount of scratching behavior and suppress the increased SP levels in the skin lesions in mice chronic inflammatory dermatitis [10, 11]. It is suggested that chemical mediators including histamine and SP in tears also involved in itching and ocular symptoms. In the clinical study, neuropeptides are up-regulated and their release in nasal fluids has been demonstrated after allergen exposure [17]. The symptoms of allergic rhinitis are not only with nasal symptoms but also with severe ocular itching. Ocular itching adversely affect the quality of life of patients with allergic rhinitis and allergic rhinoconjunctivitis.

These results indicate that olopatadine ophthalmic solution appears to exert additional SP release inhibition besides its well-established dual-action as selective histamine H1 receptor antagonistic action and human conjunctival mast cell stabilization action. Olopatadine ophthalmic solution may be useful as the first choice for the treatment of AC.

REFERENCES

1. Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996;278:1252-61.
2. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther 1996;12:389-400.
3. Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu S, Sharif NA. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol 1997;79:541-5.
4. Yanni JM, Weimer LK, Sharif NA, Xu SX, Gamache DA, Spellman JM. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999;117:643-7.
5. Fujishima H, Takeyama M, Takeuchi T, Saito I, Tsubota K. Elevated levels of substance P in tears of patients with allergic conjunctivitis and vernal keratoconjunctivitis. Clin Exp Allergy
Olopatadine drop suppresses substance P release

1997;27:372-8.

6. Micera A, Lambiase A, Bonini S. The role of neuromediators in ocular allergy. Curr Opin Allergy Clin Immunol 2008;8:466-71.

7. Mantelli F, Micera A, Sacchetti M, Bonini S. Neurogenic inflammation of the ocular surface. Curr Opin Allergy Clin Immunol 2010;10:498-504.

8. Rossi R, Johansson O. Cutaneous innervation and the role of neuronal peptides in cutaneous inflammation: a minireview. Eur J Dermatol 1998;8:299-306.

9. Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol 2011;11:420-7.

10. Tamura T, Amano T, Ohmori K, Manabe H. The effects of olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice. Eur J Pharmacol 2005;524:149-54.

11. Murota H, El-latif MA, Tamura T, Amano T, Katayama I. Olopatadine hydrochloride improves dermatitis score and inhibits scratch behavior in NC/Nga mice. Int Arch Allergy Immunol 2010;153:121-32.

12. Stotland LM, Share NN. Active bronchial anaphylaxis in the rat. Can J Physiol Pharmacol 1974;52:1114-8.

13. Minami K, Hossen MA, Kamei C. Increasing effect by simultaneous use of levocabastine and pemirolast on experimental allergic conjunctivitis in rats. Biol Pharm Bull 2005;28:473-6.

14. Shimura M, Yasuda K, Miyazawa A, Otani T, Nakazawa T. Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis. Am J Ophthalmol 2011;151:697-702.e2.

15. Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther 1996;12:401-7.

16. Foreman J, Jordan C. Histamine release and vascular changes induced by neuropeptides. Agents Actions 1983;13:105-16.

17. Mosimann BL, White MV, Hohman RJ, Goldrich MS, Kaulbach HC, Kaliner MA. Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients. J Allergy Clin Immunol 1993;92:95-104.